GNA Biosolutions adds CEO to expand its management team

Munich, 05 July 2016 – GNA Biosolutions, Martinsried (Germany) has appointed Frank Krieg-Schneider as its Managing Director and CEO.

 

Frank is a senior executive in the diagnostics and life sciences industry with more than 20 years of experience in product development and commercialisation. After obtaining his PhD in molecular genetics from the University of Mainz, followed by a postdoctoral fellowship at the University Medical Centre Mannheim, Frank joined QIAGEN, a leading global provider of Life Science and Molecular Diagnostics products.

 

At QIAGEN, he was first instrumental in establishing the diagnostic sample preparation product range, and later in defining the strategy and product roadmap for the molecular diagnostics and point of care markets. In his former role as VP, Global Head of Strategic Alliances and OEM he successfully created new business opportunities for QIAGEN, such as the OEM business, Second Brands, and Customised Products. Frank managed independent businesses and employees across sites in Germany, Sweden and the United States. He drove revenues from zero to the high double-digit million USD range.

 

At GNA Biosolutions he is now expanding strategic alliances and promoting GNA’s commercialization. He will support GNA with his solid business experience, securing new OEM partnerships. This will allow the implementation of Laser PCR – GNA’s ultra-fast technology for molecular diagnostics – in selected partners’ applications and systems, in addition to GNA’s internal products.

 

He complements the existing management team, comprising the founders and co-Managing Directors Joachim Stehr, Federico Bürsgens and Lars Ullerich. The founders commented: “Frank is a perfect addition to our management team. He has a proven track record in building high-growth and profitable product portfolios.”  Frank Krieg-Schneider added: “I’m looking forward to break new ground with this strong team and our innovative technology, which applies the speed of light to PCR.”